金埔园林股份有限公司（以下简称"公司"）于 2025 年 9 月 11 日披露了《关 于股东拟减持公司股份的预披露公告》（公告编号：2025-115）。持有公司股份 4,751,900 股，占公司总股本比例 2.58%的股东南京高科新创投资有限公司（以下 简称"高科新创"）计划自本公告披露之日起三个交易日后的第一个交易日起三个 月内以集中竞价方式减持本公司股份不超过 1,839,300 股（不超过剔除公司回购 专用账户股份后总股本比例 1%）；通过大宗交易方式减持股份合计不超过 2,912,600 股（约占剔除公司回购专用账户股份后总股本比例 1.58%）。 公司于近日收到高科新创出具的《关于股份减持计划期限届满的告知函》， 本次减持股份期限已届满，现将减持计划实施情况公告如下： 一、股东减持情况 | 证券代码：301098 | 证券简称：金埔园林 | 公告编号：2025-145 | | --- | --- | --- | | 债券代码：123198 | 债券简称：金埔转债 | | 金埔园林股份有限公司 关于股东减持计划期限届满暨实施情况的公告 公司股东南京高科新创投资有限公司保证向本公司提供的信息 内容真实 ...

证券日报网讯12月15日，金埔园林（301098）在互动平台回答投资者提问时表示，截至2025年12月10日 公司合并普通账户和融资融券信用账户的在册股东总数为10565户。 ...

| 证券代码：301098 | 证券简称：金埔园林 | 公告编号：2025-144 | | --- | --- | --- | | 债券代码：123198 | 债券简称：金埔转债 | | 金埔园林股份有限公司 关于 2025 年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.本次股东会无否决议案的情形； 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.召开时间： （1）现场会议时间：2025年12月9日（星期二）15:00 （2）网络投票时间：2025年12月9日。其中： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 12 月 9 日 9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 12 月 9 日 9:15-15:00。 2.现场会议召开地点：南京市江宁区东山街道润麒路70号三楼会议室。 3.会议召集人：金埔园林股份有限公司董事会。 4.会议召开方式：现场投 ...

金埔园林 2025年第四次临时股东会 法律意见书 江苏世纪同仁律师事务所 关于金埔园林股份有限公司 2025 年第四次临时股东会的法律意见书 金埔园林股份有限公司: 金埔园林 2025年第四次临时股东会 法律意见书 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民 共和国证券法》(以下简称"《证券法》")和中国证券监督管理委员会发布的 《上市公司股东会规则》等法律、法规和规范性文件以及《金埔园林股份有限公 司章程》(以下简称"《公司章程》")的规定,本所受公司董事会的委托,指 派本所律师出席公司 2025年第四次临时股东会,并就本次股东会的召集、召开 程序,出席会议人员资格、召集人资格、表决程序以及表决结果的合法有效性等 事项出具法律意见。 为出具本法律意见书,本所律师对本次股东会所涉及的有关事项进行了审 查,查阅了相关会议文件,并对有关问题进行了必要的核查和验证。 本所律师同意将本法律意见书随公司本次股东会决议一并公告,并依法对本 法律意见书承担相应的责任。 本所律师根据相关法律、法规和规范性文件的要求,按照律师行业公认的业 务标准、道德规范和勤勉尽责精神,出具法律意见如下: 一、关于本次 ...

证券日报网讯 12月5日晚间，金埔园林发布公告称，公司无逾期对外担保、无违规担保等情况。 （文章来源：证券日报） ...

| 证券代码：301098 | 证券简称：金埔园林 | 公告编号：2025-143 | | --- | --- | --- | | 债券代码：123198 | 债券简称：金埔转债 | | 金埔园林股份有限公司 关于对外担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 金埔园林股份有限公司（以下简称"金埔园林"、"公司"）于2025年4月18日 召开第五届董事会第二十一次会议、第五届监事会第十二次会议，分别审议通过 了《关于预计对外担保额度的议案》，同意公司与合并报表范围内子公司拟向银 行及其它机构申请授信及贷款时，互相提供担保，担保金额上限为48,000万元。 担保范围包括但不限于债权本金及按主合同约定计收的全部利息。担保方式包括 但不限于保证担保、资产抵押、质押等。在上述额度内，公司可根据实际经营需 要对公司与公司合并报表范围内的子公司之间及子公司相互之间的担保金额进 行调剂，不需要单独进行审批。本次对外担保额度授权期限为公司2024年年度股 东大会审议通过之日起至2025年年度股东大会召开日止。具体内容详见公司于 2025年 ...

证券日报网讯12月2日，金埔园林（301098）在互动平台回答投资者提问时表示，截至2025年11月28日 公司合并普通账户和融资融券信用账户的在册股东总数为10600户。 ...

债券受托管理人： 股票简称：金埔园林 股票代码：301098 债券简称：金埔转债 债券代码：123198 长江证券承销保荐有限公司 关于金埔园林股份有限公司向不特定对象 发行可转换公司债券的临时受托管理事务 报告 金埔园林股份有限公司向不特定对象发行可转换公司债券 2025 年度第 6 次临时受托管理事务报告 中国（上海）自由贸易试验区世纪大道1198号28层 2025 年 12 月 金埔园林股份有限公司向不特定对象发行可转换公司债券 2025 年度第 6 次临时受托管理事务报告 声 明 长江证券承销保荐有限公司（以下简称"长江保荐"、"保荐人"或"受托管 理人"）编制本报告的内容及信息均来源于发行人相关信息披露文件、金埔园林 股份有限公司（以下简称"金埔园林"、"发行人"或"公司"）提供的证明文件 及第三方中介机构出具的专业意见。长江保荐对报告中所包含的相关引述内容和 信息未进行独立验证，也不就该等引述内容和信息的真实性、准确性和完整性做 出任何保证或承担任何责任。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为长江保荐所作的承诺 或 ...

Group 1: Storage Market Dynamics - The storage spot market is experiencing strong demand, leading to continued price increases for finished products, despite high prices [1] - Customers with low inventory levels are gradually accepting new pricing agreements, providing manufacturers with confidence to raise prices [1] - The significant price increases are affecting retail markets, with online and offline retailers raising prices for memory modules and SSDs, potentially reducing consumer purchasing willingness [1] Group 2: DRAM Industry Forecast - According to TrendForce, the DRAM industry revenue is expected to grow by 30.9% quarter-on-quarter in Q3 2025, reaching $41.4 billion due to rising contract prices and increased shipment volumes [1] - The fourth quarter is anticipated to see a significant increase in contract prices, with conventional DRAM prices expected to rise by 45%-50% [1] - The overall contract prices for conventional DRAM and HBM combined are projected to increase by 50%-55% [1] Group 3: Medical Device Market Growth - The Chinese medical device market is projected to reach ¥1.22 trillion by 2025, with over 33,000 production enterprises expected by the end of 2024, marking a 27.8% increase from the end of the 13th Five-Year Plan [2] - The industry is transitioning from "catching up" to "running alongside and leading," supporting the "Healthy China" strategy [2] Group 4: Flu Season Impact on Pharmaceuticals - The flu season has started early in China, with a 237% increase in sales of Oseltamivir over the past week, and a 180% increase for Maviral [2] - The peak of the flu season is expected between mid-December and early January [2] Group 5: Cinema Industry Growth - As of October 2023, China has added 233 cinemas and 1,588 screens, totaling 15,438 operating cinemas and 92,556 screens nationwide [3] - County-level cinemas account for 21.06% of the total, while town cinemas make up 18.01% [3] Group 6: Innovations in Medical Technology - Novo Nordisk's Kyinsu, the world's first weekly insulin and GLP-1 receptor agonist combination, has been approved in the EU for adults with type 2 diabetes [3] - This innovation represents a significant advancement in diabetes treatment options [3] Group 7: Corporate Developments - Allianz Partners plans to lay off 1,500 to 1,800 employees over the next 12-18 months, primarily in call center roles due to automation [5] - Novartis announced plans to cut up to 550 jobs in Switzerland by the end of 2027 as part of production adjustments [5]

Group 1 - Aolide plans to raise no more than 300 million yuan through a simplified procedure for issuing shares to specific targets, with net proceeds allocated to the production base project for OLED display core materials and to supplement working capital [1] - Wanbang's subsidiary has obtained a 10-year exclusive agency for sildenafil oral suspension, which is suitable for patients with swallowing difficulties [2] - Titan Technology and its affiliate plan to jointly invest in increasing capital for its subsidiary, Micro Detection, raising its registered capital from 10 million yuan to 50 million yuan [3] Group 2 - Jindike will not issue new batches of quadrivalent influenza virus split vaccine this year, having produced approximately 1.56 million doses [4] - Aladdin intends to purchase 35% equity of Youke for 61.25 million yuan, funded by its own or raised capital [5] - Gujia Home's application for a private placement of A-shares has been approved by the Shanghai Stock Exchange [7] Group 3 - Honghe Technology's application for a private placement of A-shares has been approved by the China Securities Regulatory Commission [9] - Guangdian Yuntong has won contracts totaling 308 million yuan for the construction of an artificial intelligence application pilot base [10] - Shanghai Mechanical plans to repurchase B-shares worth no more than 278 million yuan [11] Group 4 - Weiling Co. is planning a change of control, with shares representing 7.76% of the total being transferred [14] - Jiugang Hongxing intends to invest 200 million yuan to establish a wholly-owned subsidiary focusing on high-quality special steel materials [16] - Zhongjian Technology has submitted an application for H-share listing [17] Group 5 - Sainuo Medical has received registration approval for its coronary product in Pakistan [18] - Huafeng Aluminum plans to acquire 100% equity of Huafeng Puen for 100 million yuan [20] - Fuda Co. intends to establish a wholly-owned subsidiary with an investment of 30 million yuan [22] Group 6 - Su Yan Jingshen's application for a private placement of shares has been approved by the Shanghai Stock Exchange [24] - Zhongchuang Co. has set the inquiry transfer price at 25.75 yuan per share [25] - Jinpu Garden has had a lawsuit involving 26.557 million yuan accepted by the court [29] Group 7 - ICBC has approved the appointment of Zhao Guid as vice president [30] - Betta Pharmaceuticals has had its drug registration application for ensartinib accepted [32] - Times New Materials plans to invest 6 million euros to establish a wholly-owned subsidiary in Serbia [34] Group 8 - China State Construction has appointed Chen Yong as vice president [36] - Dayang Electric plans to invest 10 million yuan to establish an industrial fund [38] - Advanced Digital has appointed Liu Zhigang as deputy general manager [39] Group 9 - Tianqi Co. plans to transfer 7% equity of Youqi Intelligent for 130 million yuan [40] - Xinguo has submitted an application for H-share issuance and listing [42] - Jinhongshun's shareholder has terminated a share reduction plan [43] Group 10 - Wanrun Co.'s actual controller plans to increase shareholding between 365 million yuan and 730 million yuan [44] - Suzhou High-tech plans to sell 47% equity of its medical device subsidiary for 604 million yuan [45] - Huayou Cobalt's subsidiary has signed a product supply agreement with Yiwei Lithium Energy for approximately 127,800 tons of materials [47] Group 11 - China Communications has won 10 important projects totaling approximately 2.539 billion yuan [49] - Nopushin plans to raise no more than 1.45 billion yuan through a private placement [50] - Yun Aluminum plans to acquire minority stakes in three subsidiaries for a total of 2.267 billion yuan [51] Group 12 - Xiamen Tungsten plans to establish a 500 million yuan merger fund with multiple parties [52] - Aotewei has signed a contract worth approximately 700 million yuan [54] - Hemai Co.'s shareholders plan to reduce their holdings by no more than 3% [56]